Get the Stockscreener App
39.46
6.48%
2.40
Pre-market:
41.99
2.53
+6.41%
Apogee Therapeutics Inc stock is traded at $39.46, with a volume of 546.04K.
It is up +6.48% in the last 24 hours and down -17.29% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
See More
Previous Close:
$37.06
Open:
$37.69
24h Volume:
546.04K
Relative Volume:
1.17
Market Cap:
$2.25B
Revenue:
-
Net Income/Loss:
$-118.49M
P/E Ratio:
-16.41
EPS:
-2.4041
Net Cash Flow:
$-110.57M
1W Performance:
+0.31%
1M Performance:
-17.29%
6M Performance:
-16.93%
1Y Performance:
+17.13%
1-Day Range:
$37.64
$39.67
1-Week Range:
$36.48
$42.98
52-Week Range:
$32.78
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.46 | 2.25B | 0 | -118.49M | -110.57M | -2.4041 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
(APGE) Investment Report - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 4.6%Should You Sell? - MarketBeat
Comparing Apogee Therapeutics (NASDAQ:APGE) and BioCardia (NASDAQ:BCDA) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $89.71 - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares - MarketBeat
CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus.com
Apogee Therapeutics CEO sells shares worth $732,692 By Investing.com - Investing.com Australia
Apogee Therapeutics CEO sells shares worth $732,692 - Investing.com India
Apogee Therapeutics (NASDAQ:APGE) Shares Down 9.1%What's Next? - MarketBeat
Trend Tracker for (APGE) - Stock Traders Daily
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Sells 2,925 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics chief medical officer sells shares worth $191,739 By Investing.com - Investing.com Australia
Carl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics chief medical officer sells shares worth $191,739 - Investing.com India
Passage Bio (NASDAQ:PASG) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head Contrast - Defense World
Learn to Evaluate (APGE) using the Charts - Stock Traders Daily
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - Yahoo Finance
Geode Capital Management LLC Increases Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 3.2%What's Next? - MarketBeat
Franklin Resources Inc. Has $48.05 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Up 6.1% After Insider Buying Activity - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Up 11.2% in November - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Price Target at $83.88 - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading 6.1% Higher Following Insider Buying Activity - MarketBeat
State Street Corp Cuts Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up Following Insider Buying Activity - Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up on Insider Buying Activity - MarketBeat
Insider Buying: Mark Mckenna Acquires 20,000 Shares of Apogee Th - GuruFocus.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna Acquires 20,000 Shares of Stock - MarketBeat
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock By Investing.com - Investing.com Canada
Apogee Therapeutics : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.89 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Increase in Short Interest - MarketBeat
Barclays PLC Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics’ (APGE) “Buy” Rating Reiterated at Guggenheim - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 Shares - MarketBeat
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $83.88 - MarketBeat
Apogee Therapeutics' chief medical officer sells $221,362 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics' chief medical officer sells $221,362 in stock - Investing.com
Financial Survey: Apogee Therapeutics (NASDAQ:APGE) versus DBV Technologies (NASDAQ:DBVT) - Defense World
Guggenheim maintains buy on Apogee stock amid trial failures - Investing.com
Apogee Therapeutics Initiates Dosing of APG333 in Phase 1 Clinical Trial - Defense World
Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions - Marketscreener.com
Apogee Therapeutics Advances Clinical Trials for APG333 - TipRanks
Apogee Therapeutics Announces First Participants Dosed in - GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its - The Bakersfield Californian
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):